The regression time of ocular surface squamous neoplasia using topical interferon alfa-2b does not depend on the initial tumor size

Detalhes bibliográficos
Autor(a) principal: Vilaltella,Magí
Data de Publicação: 2022
Outros Autores: Huerva,Valentín
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Arquivos brasileiros de oftalmologia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492022000200109
Resumo: ABSTRACT Purpose: The aim of this study was to determine if the initial tumor size correlates with the time to regression after topical interferon alfa-2b (1 million IU/mL) therapy in the treatment of ocular surface squamous neoplasia. Methods: A retrospective study was performed in 15 patients clinically diagnosed as having ocular surface squamous neoplasia and treated with topical interferon alfa-2b (1 million IU/mL, four times a day). All the cases of ocular surface squamous neoplasia included in the study had corneo-limbal involvement. The initial extension of the ocular surface squamous neoplasia was measured in square millimeters using the program ImageJ (LOCI, University of Wisconsin, Madison, USA) on images taken from the eyes of each patient immediately before the beginning of the treatment. The time until tumor resolution was measured for each case. Results: Complete tumor resolution was achieved in all the cases, with a mean initial tumor extension of 26.71 mm² (standard deviation ± 17.21 mm²) and a mean time until resolution of 77 days (standard deviation ± 32 days). An increased tumor volume after 15 days of treatment was obser ved in 2 patients, which completely resolved. No significant correlation was found between the time to resolution and the initial tumor extension measured in square millimeters (Spear man test, p=0.347). Conclusions: Our study suggests that the duration of topical interferon alfa-2b treatment required does not depend on the initial tumor size of the ocular surface squamous neoplasia usually found in clinical practice.
id CBO-2_0b144d66b0ebd6aa6ba0933eb407f89b
oai_identifier_str oai:scielo:S0004-27492022000200109
network_acronym_str CBO-2
network_name_str Arquivos brasileiros de oftalmologia (Online)
repository_id_str
spelling The regression time of ocular surface squamous neoplasia using topical interferon alfa-2b does not depend on the initial tumor sizeConjunctival neoplasmCorneal disease/drug therapyCarcinoma, Squamous cellInterferon alpha-2/therapeutic useABSTRACT Purpose: The aim of this study was to determine if the initial tumor size correlates with the time to regression after topical interferon alfa-2b (1 million IU/mL) therapy in the treatment of ocular surface squamous neoplasia. Methods: A retrospective study was performed in 15 patients clinically diagnosed as having ocular surface squamous neoplasia and treated with topical interferon alfa-2b (1 million IU/mL, four times a day). All the cases of ocular surface squamous neoplasia included in the study had corneo-limbal involvement. The initial extension of the ocular surface squamous neoplasia was measured in square millimeters using the program ImageJ (LOCI, University of Wisconsin, Madison, USA) on images taken from the eyes of each patient immediately before the beginning of the treatment. The time until tumor resolution was measured for each case. Results: Complete tumor resolution was achieved in all the cases, with a mean initial tumor extension of 26.71 mm² (standard deviation ± 17.21 mm²) and a mean time until resolution of 77 days (standard deviation ± 32 days). An increased tumor volume after 15 days of treatment was obser ved in 2 patients, which completely resolved. No significant correlation was found between the time to resolution and the initial tumor extension measured in square millimeters (Spear man test, p=0.347). Conclusions: Our study suggests that the duration of topical interferon alfa-2b treatment required does not depend on the initial tumor size of the ocular surface squamous neoplasia usually found in clinical practice.Conselho Brasileiro de Oftalmologia2022-04-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492022000200109Arquivos Brasileiros de Oftalmologia v.85 n.2 2022reponame:Arquivos brasileiros de oftalmologia (Online)instname:Conselho Brasileiro de Oftalmologia (CBO)instacron:CBO10.5935/0004-2749.20220018info:eu-repo/semantics/openAccessVilaltella,MagíHuerva,Valentíneng2022-04-05T00:00:00Zoai:scielo:S0004-27492022000200109Revistahttp://aboonline.org.br/https://old.scielo.br/oai/scielo-oai.phpaboonline@cbo.com.br||abo@cbo.com.br1678-29250004-2749opendoar:2022-04-05T00:00Arquivos brasileiros de oftalmologia (Online) - Conselho Brasileiro de Oftalmologia (CBO)false
dc.title.none.fl_str_mv The regression time of ocular surface squamous neoplasia using topical interferon alfa-2b does not depend on the initial tumor size
title The regression time of ocular surface squamous neoplasia using topical interferon alfa-2b does not depend on the initial tumor size
spellingShingle The regression time of ocular surface squamous neoplasia using topical interferon alfa-2b does not depend on the initial tumor size
Vilaltella,Magí
Conjunctival neoplasm
Corneal disease/drug therapy
Carcinoma, Squamous cell
Interferon alpha-2/therapeutic use
title_short The regression time of ocular surface squamous neoplasia using topical interferon alfa-2b does not depend on the initial tumor size
title_full The regression time of ocular surface squamous neoplasia using topical interferon alfa-2b does not depend on the initial tumor size
title_fullStr The regression time of ocular surface squamous neoplasia using topical interferon alfa-2b does not depend on the initial tumor size
title_full_unstemmed The regression time of ocular surface squamous neoplasia using topical interferon alfa-2b does not depend on the initial tumor size
title_sort The regression time of ocular surface squamous neoplasia using topical interferon alfa-2b does not depend on the initial tumor size
author Vilaltella,Magí
author_facet Vilaltella,Magí
Huerva,Valentín
author_role author
author2 Huerva,Valentín
author2_role author
dc.contributor.author.fl_str_mv Vilaltella,Magí
Huerva,Valentín
dc.subject.por.fl_str_mv Conjunctival neoplasm
Corneal disease/drug therapy
Carcinoma, Squamous cell
Interferon alpha-2/therapeutic use
topic Conjunctival neoplasm
Corneal disease/drug therapy
Carcinoma, Squamous cell
Interferon alpha-2/therapeutic use
description ABSTRACT Purpose: The aim of this study was to determine if the initial tumor size correlates with the time to regression after topical interferon alfa-2b (1 million IU/mL) therapy in the treatment of ocular surface squamous neoplasia. Methods: A retrospective study was performed in 15 patients clinically diagnosed as having ocular surface squamous neoplasia and treated with topical interferon alfa-2b (1 million IU/mL, four times a day). All the cases of ocular surface squamous neoplasia included in the study had corneo-limbal involvement. The initial extension of the ocular surface squamous neoplasia was measured in square millimeters using the program ImageJ (LOCI, University of Wisconsin, Madison, USA) on images taken from the eyes of each patient immediately before the beginning of the treatment. The time until tumor resolution was measured for each case. Results: Complete tumor resolution was achieved in all the cases, with a mean initial tumor extension of 26.71 mm² (standard deviation ± 17.21 mm²) and a mean time until resolution of 77 days (standard deviation ± 32 days). An increased tumor volume after 15 days of treatment was obser ved in 2 patients, which completely resolved. No significant correlation was found between the time to resolution and the initial tumor extension measured in square millimeters (Spear man test, p=0.347). Conclusions: Our study suggests that the duration of topical interferon alfa-2b treatment required does not depend on the initial tumor size of the ocular surface squamous neoplasia usually found in clinical practice.
publishDate 2022
dc.date.none.fl_str_mv 2022-04-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492022000200109
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492022000200109
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.5935/0004-2749.20220018
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Conselho Brasileiro de Oftalmologia
publisher.none.fl_str_mv Conselho Brasileiro de Oftalmologia
dc.source.none.fl_str_mv Arquivos Brasileiros de Oftalmologia v.85 n.2 2022
reponame:Arquivos brasileiros de oftalmologia (Online)
instname:Conselho Brasileiro de Oftalmologia (CBO)
instacron:CBO
instname_str Conselho Brasileiro de Oftalmologia (CBO)
instacron_str CBO
institution CBO
reponame_str Arquivos brasileiros de oftalmologia (Online)
collection Arquivos brasileiros de oftalmologia (Online)
repository.name.fl_str_mv Arquivos brasileiros de oftalmologia (Online) - Conselho Brasileiro de Oftalmologia (CBO)
repository.mail.fl_str_mv aboonline@cbo.com.br||abo@cbo.com.br
_version_ 1754209031804682240